SECOND ARTICLE: SAN DIEGO, June 23, 2020 /PRNewswire/ — Reneo Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted Orphan Drug Designation to the company’s lead drug candidate, REN001, for the treatment of primary mitochondrial myopathies (PMM). The company also announced positive […]